These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
530 related articles for article (PubMed ID: 28233184)
1. Inflammatory Bowel Disease: Pathophysiology and Current Therapeutic Approaches. Abraham BP; Ahmed T; Ali T Handb Exp Pharmacol; 2017; 239():115-146. PubMed ID: 28233184 [TBL] [Abstract][Full Text] [Related]
3. Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases. Billmeier U; Dieterich W; Neurath MF; Atreya R World J Gastroenterol; 2016 Nov; 22(42):9300-9313. PubMed ID: 27895418 [TBL] [Abstract][Full Text] [Related]
4. New insights into inflammatory bowel disease pathophysiology: paving the way for novel therapeutic targets. Stefanelli T; Malesci A; Repici A; Vetrano S; Danese S Curr Drug Targets; 2008 May; 9(5):413-8. PubMed ID: 18473770 [TBL] [Abstract][Full Text] [Related]
5. Which patients with inflammatory bowel disease should receive combination therapy? Cross RK Expert Rev Gastroenterol Hepatol; 2015 Jun; 9(6):715-7. PubMed ID: 25912620 [TBL] [Abstract][Full Text] [Related]
6. [Inflammatory bowel disease: an overview]. Herrlinger K Med Monatsschr Pharm; 2013 Nov; 36(11):402-8; quiz 409. PubMed ID: 24640117 [TBL] [Abstract][Full Text] [Related]
7. Anti-adhesion Molecules in IBD: Does Gut Selectivity Really Make the Difference? D'Amico F; Roda G; Peyrin-Biroulet L; Danese S Curr Pharm Des; 2019; 25(1):19-24. PubMed ID: 30848193 [TBL] [Abstract][Full Text] [Related]
8. An update on biosimilar drugs for inflammatory bowel disease. Schreiber S Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():1-3. PubMed ID: 26395529 [TBL] [Abstract][Full Text] [Related]
9. Anti-TNF alpha therapy in the management of extraintestinal manifestation of inflammatory bowel disease. Andrisani G; Guidi L; Papa A; Armuzzi A Eur Rev Med Pharmacol Sci; 2012 Jul; 16(7):890-901. PubMed ID: 22953637 [TBL] [Abstract][Full Text] [Related]
11. Potential role of nutraceutical compounds in inflammatory bowel disease. Larussa T; Imeneo M; Luzza F World J Gastroenterol; 2017 Apr; 23(14):2483-2492. PubMed ID: 28465632 [TBL] [Abstract][Full Text] [Related]
12. UK guidance opens new therapeutic avenues for patients with moderate-severe ulcerative colitis. Orchard T Expert Rev Gastroenterol Hepatol; 2016; 10(3):281-2. PubMed ID: 26651595 [No Abstract] [Full Text] [Related]
13. Inflammatory pathways of importance for management of inflammatory bowel disease. Pedersen J; Coskun M; Soendergaard C; Salem M; Nielsen OH World J Gastroenterol; 2014 Jan; 20(1):64-77. PubMed ID: 24415859 [TBL] [Abstract][Full Text] [Related]
14. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies. Magro F; Portela F BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228 [TBL] [Abstract][Full Text] [Related]
15. Infliximab in ulcerative colitis. Aberra FN; Lichtenstein GR Gastroenterol Clin North Am; 2006 Dec; 35(4):821-36. PubMed ID: 17129815 [TBL] [Abstract][Full Text] [Related]
16. Therapeutic Potential of Amino Acids in Inflammatory Bowel Disease. Liu Y; Wang X; Hu CA Nutrients; 2017 Aug; 9(9):. PubMed ID: 28832517 [TBL] [Abstract][Full Text] [Related]
17. Surgery for Crohn's disease and anti-TNF agents: the changing scenario. Sorrentino D; Fogel S; Van den Bogaerde J Expert Rev Gastroenterol Hepatol; 2013 Nov; 7(8):689-700. PubMed ID: 24161133 [TBL] [Abstract][Full Text] [Related]
18. Vedolizumab for ulcerative colitis and Crohn's disease: results and implications of GEMINI studies. Lam MC; Bressler B Immunotherapy; 2014; 6(9):963-71. PubMed ID: 25341118 [TBL] [Abstract][Full Text] [Related]
19. Safety of anti-tumor necrosis factor therapy during pregnancy in patients with inflammatory bowel disease. Androulakis I; Zavos C; Christopoulos P; Mastorakos G; Gazouli M World J Gastroenterol; 2015 Dec; 21(47):13205-11. PubMed ID: 26715803 [TBL] [Abstract][Full Text] [Related]